First Tracks Biotherapeutics, Inc. (TRAX) Stock Profile — Insider Trades & Financials

Smart-Money SignalAccumulation · 68/100— Insiders are net buyers over 90 days ($65.0M, 53 buys vs 1 sale)

Net Income-$50.5M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Daniel Faga

CEO & Executive Director

First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. First Tracks Biotherapeutics, Inc. operates as a subsidiary of AnaptysBio, Inc.

Founded: 2025
Employees: 104
Headquarters: SAN DIEGO, CA, United States
Website

Smart-Money Signal

90-DAY POSTURE

68/ 100

ACCUMULATION

Insiders are net buyers over 90 days ($65.0M, 53 buys vs 1 sale). Smart-money posture skews to accumulation.

Insider flow · 90d$65.0M

Congress flow · 90dno activity

10b5-1 share—

Cluster selling1 officer

Loading company sections...

First Tracks Biotherapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

The morning brief, before the bell.

First Tracks Biotherapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades